{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T09:18:29Z","timestamp":1792919909349,"version":"4.5.0"},"reference-count":39,"publisher":"American Society of Hematology","issue":"7","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,4,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Nelarabine, an antimetabolite prodrug, is approved as monotherapy for children and adults\u00a0with relapsed and refractory T-cell acute lymphoblastic leukemia and lymphoma (R\/R T-ALL\/LBL), although it is often used in combination regimens. We sought to understand differences in efficacy and toxicity when nelarabine is administered alone or in combination. We retrospectively analyzed 44 consecutive patients with R\/R T-ALL\/LBL; 29 of whom were treated with combination therapy, most with cyclophosphamide and etoposide (23, 79%) and 15 with monotherapy. The median age was 19 years (range, 2-69), including 18 children (&amp;lt;18 years). After a median of 1 (range, 1-3) cycle of treatment, 24 patients (55%) achieved complete remission, 62% (18\/29) with combination therapy and 40% (6\/15) with monotherapy (P\u00a0= .21). Most responders (21, 88%) pursued allogeneic stem cell transplant (alloSCT). Overall survival (OS) was 12.8 months (95% confidence interval, 6.93-not reached) in the entire cohort and was higher in the combination therapy than in the monotherapy group (24-month OS, 53% vs 8%; P\u00a0= .003). The rate of neurotoxicity was similar between groups (27% vs 17%; P\u00a0= .46) and grade 3\/4 anemia and thrombocytopenia were more frequent in the combination group (76% vs 20%; P\u00a0&amp;lt; .001% and 66% vs 27%; P\u00a0=\u00a0.014, respectively). In a multivariate analysis, nelarabine combination therapy and alloSCT post nelarabine were associated with improved OS (hazard ratio, 0.41; P\u00a0= .04 and hazard ratio, 0.25; P\u00a0= .008, respectively). In conclusion, compared with monotherapy, nelarabine combination therapy was well tolerated and associated with improved survival in pediatric and adult patients with R\/R T-ALL\/LBL.<\/jats:p>","DOI":"10.1182\/bloodadvances.2022008280","type":"journal-article","created":{"date-parts":[[2022,12,12]],"date-time":"2022-12-12T12:08:46Z","timestamp":1670846926000},"page":"1092-1102","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":49,"title":["Nelarabine combination therapy for relapsed or refractory T-cell acute lymphoblastic lymphoma\/leukemia"],"prefix":"10.1182","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7245-9652","authenticated-orcid":false,"given":"Shai","family":"Shimony","sequence":"first","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"},{"name":"2Rabin Medical Center and Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiwen","family":"Liu","sequence":"additional","affiliation":[{"name":"3Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8927-8006","authenticated-orcid":false,"given":"Yannis K.","family":"Valtis","sequence":"additional","affiliation":[{"name":"4Department of Medicine, Brigham and Women\u2019s Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6891-8497","authenticated-orcid":false,"given":"Jonathan D.","family":"Paolino","sequence":"additional","affiliation":[{"name":"5Dana-Farber\/Boston Children\u2019s Cancer and Blood Disorders Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9604-4213","authenticated-orcid":false,"given":"Andrew E.","family":"Place","sequence":"additional","affiliation":[{"name":"5Dana-Farber\/Boston Children\u2019s Cancer and Blood Disorders Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew M.","family":"Brunner","sequence":"additional","affiliation":[{"name":"6Center for Leukemia, Massachusetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8726-6212","authenticated-orcid":false,"given":"Lachelle D.","family":"Weeks","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lewis B.","family":"Silverman","sequence":"additional","affiliation":[{"name":"5Dana-Farber\/Boston Children\u2019s Cancer and Blood Disorders Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynda M.","family":"Vrooman","sequence":"additional","affiliation":[{"name":"5Dana-Farber\/Boston Children\u2019s Cancer and Blood Disorders Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna S.","family":"Neuberg","sequence":"additional","affiliation":[{"name":"3Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard M.","family":"Stone","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"DeAngelo","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5781-4529","authenticated-orcid":false,"given":"Marlise R.","family":"Luskin","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,3,29]]},"reference":[{"issue":"5","key":"2023090715334014000_bib1","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1182\/blood.V84.5.1603.1603","article-title":"Immunophenotype of adult acute lymphoblastic leukemia, clinical parameters, and outcome: an analysis of\u00a0a\u00a0prospective trial including 562 tested patients (LALA87). French group on therapy for adult acute lymphoblastic leukemia","volume":"84","author":"Boucheix","year":"1994","journal-title":"Blood"},{"issue":"11","key":"2023090715334014000_bib2","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.3324\/haematol.2012.080432","article-title":"Clinico-biological features of 5202 patients with acute lymphoblastic leukemia enrolled in the Italian AIEOP and GIMEMA protocols and stratified in age cohorts","volume":"98","author":"Chiaretti","year":"2013","journal-title":"Haematologica"},{"issue":"5","key":"2023090715334014000_bib3","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1182\/blood-2008-01-130237","article-title":"What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies","volume":"112","author":"Stock","year":"2008","journal-title":"Blood"},{"issue":"3","key":"2023090715334014000_bib4","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/leu.2014.229","article-title":"Long-term outcome of a pediatric-inspired regimen used for adults aged 18\u201350 years with newly diagnosed acute lymphoblastic leukemia","volume":"29","author":"Deangelo","year":"2015","journal-title":"Leukemia"},{"issue":"14","key":"2023090715334014000_bib5","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1182\/blood-2018-10-881961","article-title":"A\u00a0pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403","volume":"133","author":"Stock","year":"2019","journal-title":"Blood"},{"issue":"8","key":"2023090715334014000_bib6","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1182\/blood-2011-03-338707","article-title":"Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study","volume":"118","author":"Schrappe","year":"2011","journal-title":"Blood"},{"issue":"7","key":"2023090715334014000_bib7","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1182\/blood-2009-09-245951","article-title":"Intravenous PEG-asparaginase during remission induction in children and adolescents with newly diagnosed acute lymphoblastic leukemia","volume":"115","author":"Silverman","year":"2010","journal-title":"Blood"},{"issue":"8","key":"2023090715334014000_bib8","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/S1470-2045(14)70243-8","article-title":"Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial","volume":"15","author":"Vora","year":"2014","journal-title":"Lancet Oncol"},{"issue":"15_suppl","key":"2023090715334014000_bib9","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.10008","article-title":"Prognostic factors for survival after relapsed acute lymphoblastic leukemia (ALL): A Children\u2019s Oncology Group (COG) study","volume":"37","author":"Rheingold","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"2023090715334014000_bib10","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1182\/blood-2006-05-018192","article-title":"Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12\/ECOG 2993 study","volume":"109","author":"Fielding","year":"2007","journal-title":"Blood"},{"issue":"4","key":"2023090715334014000_bib11","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1182\/blood.V61.4.660.660","article-title":"Selective toxicity of deoxyguanosine and arabinosyl guanine for T- leukemic cells","volume":"61","author":"Cohen","year":"1983","journal-title":"Blood"},{"key":"2023090715334014000_bib12","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/978-1-4757-0390-0_59","article-title":"Sensitivity of T-leukemic cells to deoxyguanosine and arabinosyl guanine","volume":"165 Pt B","author":"Gelfand","year":"1984","journal-title":"Adv Exp Med Biol"},{"issue":"15","key":"2023090715334014000_bib13","first-page":"3352","article-title":"2-Amino-6-methoxypurine arabinoside: an agent for T-cell malignancies","volume":"55","author":"Lambe","year":"1995","journal-title":"Cancer Res"},{"issue":"5","key":"2023090715334014000_bib14","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1182\/blood-2003-01-0317","article-title":"Mechanisms for T-cell selective cytotoxicity of arabinosylguanine","volume":"102","author":"Rodriguez","year":"2003","journal-title":"Blood"},{"issue":"3","key":"2023090715334014000_bib15","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1172\/JCI111514","article-title":"Specific cytotoxicity of arabinosylguanine toward cultured T lymphoblasts","volume":"74","author":"Ullman","year":"1984","journal-title":"J\u00a0Clin Invest"},{"issue":"15","key":"2023090715334014000_bib16","doi-asserted-by":"crossref","first-page":"3376","DOI":"10.1200\/JCO.2005.03.426","article-title":"Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children's Oncology Group","volume":"23","author":"Berg","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"2023090715334014000_bib17","doi-asserted-by":"crossref","first-page":"5136","DOI":"10.1182\/blood-2006-11-056754","article-title":"Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801","volume":"109","author":"DeAngelo","year":"2007","journal-title":"Blood"},{"issue":"13","key":"2023090715334014000_bib18","doi-asserted-by":"crossref","first-page":"3504","DOI":"10.1182\/blood-2011-01-329441","article-title":"High single-drug activity of nelarabine in relapsed T-lymphoblastic leukemia\/lymphoma offers curative option with subsequent stem cell transplantation","volume":"118","author":"Gokbuget","year":"2011","journal-title":"Blood"},{"issue":"3","key":"2023090715334014000_bib19","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/j.1365-2141.2010.08236.x","article-title":"Salvage therapy with nelarabine, etoposide, and cyclophosphamide in relapsed\/refractory paediatric T-cell lymphoblastic leukaemia and lymphoma","volume":"150","author":"Commander","year":"2010","journal-title":"Br J Haematol"},{"issue":"21","key":"2023090715334014000_bib20","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V124.21.795.795","article-title":"Nelarabine in combination with etoposide and cyclophosphamide is active in first relapse of childhood T-acute lymphocytic leukemia (T-ALL) and T-lymphoblastic lymphoma (T-LL)","volume":"124","author":"Whitlock","year":"2014","journal-title":"Blood"},{"issue":"2","key":"2023090715334014000_bib21","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1111\/bjh.13771","article-title":"Nelarabine, cyclosphosphamide and etoposide for adults with relapsed T-cell acute lymphoblastic leukaemia and lymphoma","volume":"174","author":"Luskin","year":"2016","journal-title":"Br J Haematol"},{"issue":"9","key":"2023090715334014000_bib22","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1182\/blood-2016-07-692608","article-title":"Management of adults with T-cell lymphoblastic leukemia","volume":"129","author":"Marks","year":"2017","journal-title":"Blood"},{"issue":"5","key":"2023090715334014000_bib23","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1111\/bjh.14916","article-title":"Current challenges and opportunities in treating adult patients with Philadelphia-negative acute lymphoblastic leukaemia","volume":"179","author":"Wolach","year":"2017","journal-title":"Br J Haematol"},{"issue":"16","key":"2023090715334014000_bib24","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1182\/blood.2019004043","article-title":"How I treat relapsed acute lymphoblastic leukemia in the pediatric population","volume":"136","author":"Hunger","year":"2020","journal-title":"Blood"},{"issue":"2","key":"2023090715334014000_bib25","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S1470-2045(08)70314-0","article-title":"Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia","volume":"10","author":"Coustan-Smith","year":"2009","journal-title":"Lancet Oncol"},{"issue":"28","key":"2023090715334014000_bib26","doi-asserted-by":"crossref","first-page":"3282","DOI":"10.1200\/JCO.20.00256","article-title":"Children\u2019s Oncology Group AALL0434: a phase III randomized clinical trial testing nelarabine in newly diagnosed T-cell acute lymphoblastic leukemia","volume":"38","author":"Dunsmore","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"2023090715334014000_bib27","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/leu.2013.312","article-title":"The combination of hyper-CVAD plus nelarabine as frontline therapy in adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma: MD Anderson Cancer Center experience","volume":"28","author":"Jain","year":"2014","journal-title":"Leukemia"},{"issue":"1","key":"2023090715334014000_bib28","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/ajh.24947","article-title":"Hyper-CVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma","volume":"93","author":"Abaza","year":"2018","journal-title":"Am J Hematol"},{"issue":"suppl 1","key":"2023090715334014000_bib29","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1182\/blood-2021-152355","article-title":"First analysis of the UKALL14 randomized trial to determine whether the addition of nelarabine to standard chemotherapy improves event free survival in adults with T-cell acute lymphoblastic leukaemia (CRUK\/09\/006)","volume":"138","author":"Rowntree","year":"2021","journal-title":"Blood"},{"issue":"3","key":"2023090715334014000_bib30","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1182\/blood.2019001557","article-title":"How I treat newly diagnosed T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma in children","volume":"135","author":"Teachey","year":"2020","journal-title":"Blood"},{"issue":"4","key":"2023090715334014000_bib31","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1182\/blood-2007-06-098012","article-title":"BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia","volume":"111","author":"Del Gaizo Moore","year":"2008","journal-title":"Blood"},{"issue":"7","key":"2023090715334014000_bib32","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1158\/0008-5472.CAN-14-1849","article-title":"BH3 inhibitor sensitivity and Bcl-2 dependence in primary acute lymphoblastic leukemia cells","volume":"75","author":"Alford","year":"2015","journal-title":"Cancer Res"},{"issue":"4","key":"2023090715334014000_bib33","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.clml.2019.09.608","article-title":"Clinical experience with venetoclax combined with chemotherapy for relapsed or refractory T-cell acute lymphoblastic leukemia","volume":"20","author":"Richard-Carpentier","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"2023090715334014000_bib34","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1158\/2159-8290.CD-20-1465","article-title":"Venetoclax and navitoclax in combination with chemotherapy in patients with relapsed or refractory acute lymphoblastic leukemia and lymphoblastic lymphoma","volume":"11","author":"Pullarkat","year":"2021","journal-title":"Cancer Discov"},{"issue":"9","key":"2023090715334014000_bib35","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1182\/blood-2017-07-794214","article-title":"Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia","volume":"131","author":"Bride","year":"2018","journal-title":"Blood"},{"issue":"1","key":"2023090715334014000_bib36","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41375-019-0548-z","article-title":"Daratumumab for eradication of minimal residual disease in high-risk advanced relapse of T-cell\/CD19\/CD22-negative acute lymphoblastic leukemia","volume":"34","author":"Ofran","year":"2020","journal-title":"Leukemia"},{"issue":"3","key":"2023090715334014000_bib37","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1182\/blood-2017-01-761320","article-title":"CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies","volume":"130","author":"Gomes-Silva","year":"2017","journal-title":"Blood"},{"issue":"5","key":"2023090715334014000_bib38","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1158\/1078-0432.CCR-20-1271","article-title":"Eradication of T-ALL cells by CD7-targeted universal CAR-T cells and initial test of ruxolitinib-based CRS management, 2021-03-01 2021 test of ruxolitinib-based CRS management","volume":"27","author":"Li","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2023090715334014000_bib39","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s40164-020-00187-x","article-title":"Advances of target therapy on NOTCH1 signaling pathway in T-cell acute lymphoblastic leukemia","volume":"9","author":"Zheng","year":"2020","journal-title":"Exp Hematol Oncol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/7\/1092\/2076654\/blooda_adv-2022-008280-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/7\/1092\/2076654\/blooda_adv-2022-008280-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T11:34:14Z","timestamp":1694086454000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/7\/1092\/493707\/Nelarabine-combination-therapy-for-relapsed-or"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,29]]},"references-count":39,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,4,11]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2022008280","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,29]]}}}